Table 2.

Univariate and Multivariate Analyses of Variables on Progression-Free Survival in 147 Patients Treated With Anti-GD2 Antibody 3F8 Plus Subcutaneous GM-CSF

Variable	No. of Patients*	P		Hazard Ratio	95% CI
		Univariate Analysis	Multivariate Analysis
Frequency change in CBRM1/5-positive granulocytes†	147	.024	.005	0.51	0.32 to 0.81
MYCN amplification	140	.32	—	—	—
Prior bone marrow or stem-cell transplantation	147	.12	—	—	—
History of prior relapse‡	147	.025	.092	1.81	0.91 to 3.59
Second-line cyclophosphamide-based regimen	147	.001	.001	2.24	1.39 to 3.63
Disease status at enrollment§	147	.008	.67	0.95	0.75 to 1.21
Missing KIR ligand	147	.073	.034	0.60	0.38 to 0.96
FcGR2A polymorphism‖	147	.40	—	—	—

NOTE. Details of univariate analyses are provided in Appendix Table A1.

Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; KIR, killer immunoglobulin-like receptor.

^*Four secondary refractory patients were excluded from this analysis.

^†Frequency was defined as the percentage of granulocyte cells positive for CBRM1/5 activation marker; change was measured from day 0 to day 4 using median cut point.

^‡History of prior relapse included all patients in second complete remission/very good partial remission.

^§First complete remission/very good partial remission v primary refractory v second complete remission/very good partial remission.

^‖R/R or R/H v H/H.